CSL Delivers $2.9 Billion Profit, 110 Million Flu Vaccine Doses

CSL said developing new and better vaccines is a strategic priority for the company going forward.

Staff at CSL are seen working in the lab in Melbourne, Australia on Nov. 8, 2020. Darrian Traynor/Getty Images

Australian biotech giant CSL delivered a multi-billion dollar profit in the 2024 financial year and a major boost in revenue.

The plasma collection, therapeutic, and vaccine company reported an underlying net profit after tax and amortisation (NPATA) of US$2.91 billion (A$4.4 billion) for the 12 months ended June 30, up 11 percent (pdf).